RZLT
Rezolute, Inc.
$4.22
+0.05
(+1.20%)
Mkt Cap
406.35M
Volume
1,352,734
52W Range
1.07-11.457
Sector
Healthcare
Beta
0.61
EPS (TTM)
-0.82 USD
P/E Ratio
-4.55
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (74.41M) | (68.46M) | (51.79M) | (41.06M) | (20.90M) | (20.33M) | (30.42M) | (29.86M) | (20.28M) | (14.94M) | (11.36M) | (9.73M) |
| EPS | -0.98 | -1.33 | -1.01 | -2.26 | -2.72 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 |
| Free Cash Flow | (69.08M) | (57.37M) | (44.63M) | (39.62M) | (20.44M) | (24.17M) | (15.35M) | (14.12M) | (13.72M) | (12.58M) | (10.24M) | (3.24M) |
| FCF / Share | -0.91 | -1.11 | -0.87 | -2.18 | -2.66 | -4.20 | -8.64 | -12.68 | -16.61 | -25.39 | -24.44 | -17.25 |
| Operating CF | (69.08M) | (57.37M) | (44.48M) | (39.62M) | (20.44M) | (24.17M) | (15.30M) | (14.11M) | (13.31M) | (10.49M) | (7.08M) | (3.17M) |
| Total Assets | 175.49M | 132.74M | 123.72M | 152.42M | 42.61M | 10.96M | 12.25M | 2.50M | 10.63M | 10.90M | 11.26M | 7.40M |
| Total Debt | 1.61M | 2.23M | 2.48M | 188,000 | 14.42M | 410,000 | 10,000 | 3.43M | 10,000 | 83,128 | 176,979 | 60,000 |
| Cash & Equiv | 94.11M | 70.40M | 16.04M | 150.41M | 41.05M | 9.96M | 11.57M | 1.65M | 4.49M | 4.06M | 5.28M | 5.93M |
| Book Value | 162.13M | 121.00M | 116.17M | 149.47M | 26.10M | 7.37M | 1.75M | (3.96M) | 8.53M | 8.77M | 9.05M | 6.41M |
| Return on Equity | -0.46 | -0.57 | -0.45 | -0.27 | -0.80 | -2.76 | -17.36 | N/A | -2.38 | -1.70 | -1.25 | -1.52 |
| Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (16.17M) | (22.77M) | (18.15M) | (24.39M) | (18.91M) | (15.73M) | (15.38M) | (22.98M) | (17.05M) | (13.91M) | (14.52M) | (12.73M) |
| EPS | -0.16 | -0.22 | -0.18 | -0.26 | -0.27 | -0.22 | -0.22 | -0.45 | -0.34 | -0.27 | -0.28 | -0.25 |
| Free Cash Flow | (13.73M) | (20.32M) | (17.43M) | (22.00M) | (17.40M) | (13.67M) | (16.01M) | (18.52M) | (15.24M) | (13.02M) | (10.59M) | (11.20M) |
| FCF / Share | -0.13 | -0.20 | -0.17 | -0.23 | -0.25 | -0.20 | -0.23 | -0.36 | -0.30 | -0.25 | -0.21 | -0.22 |
| Operating CF | (13.73M) | (20.32M) | (17.43M) | (22.00M) | (17.40M) | (13.67M) | (16.01M) | (18.52M) | (15.24M) | (13.02M) | (10.59M) | (11.35M) |
| Total Assets | 125.46M | 138.63M | 158.66M | 175.49M | 94.74M | 112.01M | 123.41M | 132.74M | 87.74M | 102.15M | 113.00M | 123.72M |
| Total Debt | 1.11M | 1.28M | 1.45M | 1.61M | 1.77M | 1.93M | 2.08M | 2.23M | 2.37M | 2.51M | 2.34M | 2.48M |
| Cash & Equiv | 11.24M | 11.94M | 9.10M | 94.11M | 14.60M | 8.93M | 10.47M | 70.40M | 5.93M | 12.50M | 8.06M | 16.04M |
| Book Value | 116.83M | 128.00M | 147.17M | 162.13M | 82.57M | 99.59M | 113.44M | 121.00M | 70.86M | 91.73M | 103.56M | 116.17M |
| Return on Equity | -0.14 | -0.18 | -0.12 | -0.15 | -0.23 | -0.16 | -0.14 | -0.19 | -0.24 | -0.15 | -0.14 | -0.11 |
RZLT News
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update